InMed Pharmaceuticals Inc (IN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

InMed Pharmaceuticals Inc (IN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH140951D
  • |
  • Pages: 58
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

InMed Pharmaceuticals Inc (InMed), formerly Cannabis Technologies Inc, is a pre-clinical stage biopharmaceutical company which develops, produces and markets plant cannabinoid based medicines. The company's pipeline products include INM-750, INM-405, and INM-085. Its products finds application in treatment of glaucoma, ocular allergies, arthritis, cancer and skin diseases, epidermolysis bullosa, psoriasis and pemphigus vulgaris metabolic syndrome, among others. InMed uses its proprietary platform technology to discover new bioactive compounds within the cannabis plant that interact with certain genes responsible for specific diseases. The company carries out research and development activities investigating the disease fighting properties of cannabis revolves around one class of biologically active ingredients. InMed is headquartered in Vancouver, British Columbia, Canada.

InMed Pharmaceuticals Inc (IN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

InMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada 13

InMed Pharma Enters into Research and Development Agreement with ATERA 14

InMed Pharma Enters into Agreement with Pharmaseed 15

Revive Therapeutics to Enter into Agreement with InMed Pharma 16

InMed Pharma Enters into Agreement with University of Debrecen to Develop Novel Phytocannabinoid Therapies for Ocular Allergies 17

InMed Pharma Enters into Agreement with University of British Columbia 18

Cannabis Science Enters into Co-Development Agreement with ImmunoClin 19

Cannabis Science Enters Into Joint Venture With Dupetit Natural Products 20

Licensing Agreements 21

Cannabis Science Enters Into Licensing Agreement With Endocan 21

Equity Offering 22

InMed Pharma Raises USD11.5 Million in Public Offering of Units 22

InMed Pharma Raises USD1.6 million in Public Offering of Shares 23

InMed Pharma Raises USD7.3 Million in Private Placement of Units 24

InMed Pharma Raises USD1 Million in Private Placement of Units 25

InMed Pharma Raises USD4.3 Million in Public Offering of Units 26

InMed Pharma Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 28

InMed Pharma Raises USD0.2 Million in Private Placement of Units 29

InMed Pharma to Raise USD0.7 Million in Private Placement of Units 30

InMed Pharma Raises USD0.83 Million in Private Placement of Units 31

InMed Pharma Raises USD0.8 Million in Private Placement of Units 32

Cannabis Science Raises USD1 Million in Private Placement of Shares 33

Asset Transactions 34

X-Change Acquires Phytiva Brand Of Products From Cannabis Science 34

Acquisition 35

Cannabis Science Acquires Additional 30.1% Stake in Michigan Green Technologies 35

Cannabis Science to Acquire Canada-Based Medical Cannabis Provider 36

X-Change Acquires Germany-Based Joint Venture Company From Cannabis Science And Dupetit Natural Products 37

Cannabis Science Acquires Trimcare, Provider Of Healthcare Facilities 38

InMed Pharmaceuticals Inc-Key Competitors 39

InMed Pharmaceuticals Inc-Key Employees 40

InMed Pharmaceuticals Inc-Locations And Subsidiaries 41

Head Office 41

Recent Developments 42

Financial Announcements 42

Sep 13, 2018: InMed Pharmaceuticals reports fourth quarter and full year fiscal 2018 financial results and provides R&D and business update 42

May 11, 2018: InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update 44

Corporate Communications 46

May 04, 2018: OTC Markets Group Welcomes InMed Pharmaceuticals to OTCQX 46

May 01, 2018: InMed Names Dr. Vikramaditya G. Yadav To Scientific Advisory Board 47

Apr 11, 2018: InMed Announces Appointment of Joshua Blacher as Chief Business Officer 48

Mar 23, 2018: InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange 49

Mar 02, 2018: InMed Receives Conditional Approval to List on the Toronto Stock Exchange 50

Oct 10, 2017: InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board 51

Jan 13, 2017: InMed Pharmaceuticals Appoints Martin Bott to Board of Directors 52

Government and Public Interest 53

Sep 11, 2018: InMed Pharmaceuticals announces NSERC grant to The University of British Columbia in support of collaborative R&D work 53

Product News 54

Oct 24, 2017: InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid 54

07/27/2017: InMed Announces Publication in European Journal of Pain 55

Mar 06, 2018: InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research 56

Clinical Trials 57

Oct 17, 2017: InMed Updates Pain Program 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58

List of Figures

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

InMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

InMed Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

InMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada 13

InMed Pharma Enters into Research and Development Agreement with ATERA 14

InMed Pharma Enters into Agreement with Pharmaseed 15

Revive Therapeutics to Enter into Agreement with InMed Pharma 16

InMed Pharma Enters into Agreement with University of Debrecen to Develop Novel Phytocannabinoid Therapies for Ocular Allergies 17

InMed Pharma Enters into Agreement with University of British Columbia 18

Cannabis Science Enters into Co-Development Agreement with ImmunoClin 19

Cannabis Science Enters Into Joint Venture With Dupetit Natural Products 20

Cannabis Science Enters Into Licensing Agreement With Endocan 21

InMed Pharma Raises USD11.5 Million in Public Offering of Units 22

InMed Pharma Raises USD1.6 million in Public Offering of Shares 23

InMed Pharma Raises USD7.3 Million in Private Placement of Units 24

InMed Pharma Raises USD1 Million in Private Placement of Units 25

InMed Pharma Raises USD4.3 Million in Public Offering of Units 26

InMed Pharma Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 28

InMed Pharma Raises USD0.2 Million in Private Placement of Units 29

InMed Pharma to Raise USD0.7 Million in Private Placement of Units 30

InMed Pharma Raises USD0.83 Million in Private Placement of Units 31

InMed Pharma Raises USD0.8 Million in Private Placement of Units 32

Cannabis Science Raises USD1 Million in Private Placement of Shares 33

X-Change Acquires Phytiva Brand Of Products From Cannabis Science 34

Cannabis Science Acquires Additional 30.1% Stake in Michigan Green Technologies 35

Cannabis Science to Acquire Canada-Based Medical Cannabis Provider 36

X-Change Acquires Germany-Based Joint Venture Company From Cannabis Science And Dupetit Natural Products 37

Cannabis Science Acquires Trimcare, Provider Of Healthcare Facilities 38

InMed Pharmaceuticals Inc, Key Competitors 39

InMed Pharmaceuticals Inc, Key Employees 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

InMed Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17250
Site License
USD 500 INR 34500
Corporate User License
USD 750 INR 51750

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com